199 related articles for article (PubMed ID: 17485150)
1. Phase I/II studies to evaluate safety and immunogenicity of a recombinant gp350 Epstein-Barr virus vaccine in healthy adults.
Moutschen M; Léonard P; Sokal EM; Smets F; Haumont M; Mazzu P; Bollen A; Denamur F; Peeters P; Dubin G; Denis M
Vaccine; 2007 Jun; 25(24):4697-705. PubMed ID: 17485150
[TBL] [Abstract][Full Text] [Related]
2. Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults.
Sokal EM; Hoppenbrouwers K; Vandermeulen C; Moutschen M; Léonard P; Moreels A; Haumont M; Bollen A; Smets F; Denis M
J Infect Dis; 2007 Dec; 196(12):1749-53. PubMed ID: 18190254
[TBL] [Abstract][Full Text] [Related]
3. Recombinant Epstein-Barr virus glycoprotein 350 as a serological antigen.
Persson Berg L; Thomsson E; Hasi G; Bäckström M; Bergström T
J Virol Methods; 2020 Oct; 284():113927. PubMed ID: 32650039
[TBL] [Abstract][Full Text] [Related]
4. Immune response of mice to a latency membrane protein 2 multiepitope antigen of Epstein-Barr virus applied as DNA vaccine and/or peptide vaccine.
Li W; Chen Q; Chen H; Rao P; Xue X; Chen S; Zhu S; Zhang L
Acta Virol; 2013; 57(1):51-8. PubMed ID: 23530824
[TBL] [Abstract][Full Text] [Related]
5. A novel tetrameric gp350 1-470 as a potential Epstein-Barr virus vaccine.
Cui X; Cao Z; Sen G; Chattopadhyay G; Fuller DH; Fuller JT; Snapper DM; Snow AL; Mond JJ; Snapper CM
Vaccine; 2013 Jun; 31(30):3039-45. PubMed ID: 23665339
[TBL] [Abstract][Full Text] [Related]
6. Safety and immunogenicity of a glycoprotein D genital herpes vaccine in healthy girls 10-17 years of age: results from a randomised, controlled, double-blind trial.
; Abu-Elyazeed RR; Heineman T; Dubin G; Fourneau M; Leroux-Roels I; Leroux-Roels G; Richardus JH; Ostergaard L; Diez-Domingo J; Poder A; Van Damme P; Romanowski B; Blatter M; Silfverdal SA; Berglund J; Josefsson A; Cunningham AL; Flodmark CE; Tragiannidis A; Dobson S; Olafsson J; Puig-Barbera J; Mendez M; Barton S; Bernstein D; Mares J; Ratner P
Vaccine; 2013 Dec; 31(51):6136-43. PubMed ID: 23850416
[TBL] [Abstract][Full Text] [Related]
7. Expression and immunogenic characterization of recombinant gp350 for developing a subunit vaccine against Epstein-Barr virus.
Wang M; Jiang S; Han Z; Zhao B; Wang L; Zhou Z; Wang Y
Appl Microbiol Biotechnol; 2016 Feb; 100(3):1221-1230. PubMed ID: 26433969
[TBL] [Abstract][Full Text] [Related]
8. Expression of Epstein-Barr virus gp350 as a single chain glycoprotein for an EBV subunit vaccine.
Jackman WT; Mann KA; Hoffmann HJ; Spaete RR
Vaccine; 1999 Feb; 17(7-8):660-8. PubMed ID: 10067671
[TBL] [Abstract][Full Text] [Related]
9. Epstein-Barr virus gp350-specific antibody titers and antibody-dependent cellular cytotoxic effector function in different groups of patients: a study using cloned gp350-expressing transfected human T cell targets.
Khyatti M; Stefanescu I; Blagdon M; Menezes J
J Infect Dis; 1994 Dec; 170(6):1439-47. PubMed ID: 7995983
[TBL] [Abstract][Full Text] [Related]
10. Rabbits immunized with Epstein-Barr virus gH/gL or gB recombinant proteins elicit higher serum virus neutralizing activity than gp350.
Cui X; Cao Z; Chen Q; Arjunaraja S; Snow AL; Snapper CM
Vaccine; 2016 Jul; 34(34):4050-5. PubMed ID: 27291087
[TBL] [Abstract][Full Text] [Related]
11. Human antibody titers to Epstein-Barr Virus (EBV) gp350 correlate with neutralization of infectivity better than antibody titers to EBV gp42 using a rapid flow cytometry-based EBV neutralization assay.
Sashihara J; Burbelo PD; Savoldo B; Pierson TC; Cohen JI
Virology; 2009 Sep; 391(2):249-56. PubMed ID: 19584018
[TBL] [Abstract][Full Text] [Related]
12. Vaccine Development for Epstein-Barr Virus.
Cohen JI
Adv Exp Med Biol; 2018; 1045():477-493. PubMed ID: 29896681
[TBL] [Abstract][Full Text] [Related]
13. Immunization With Fc-Based Recombinant Epstein-Barr Virus gp350 Elicits Potent Neutralizing Humoral Immune Response in a BALB/c Mice Model.
Zhao B; Zhang X; Krummenacher C; Song S; Gao L; Zhang H; Xu M; Feng L; Feng Q; Zeng M; Xu Y; Zeng Y
Front Immunol; 2018; 9():932. PubMed ID: 29765376
[TBL] [Abstract][Full Text] [Related]
14. A novel vaccine candidate based on chimeric virus-like particle displaying multiple conserved epitope peptides induced neutralizing antibodies against EBV infection.
Zhang X; Zhao B; Ding M; Song S; Kang Y; Yu Y; Xu M; Xiang T; Gao L; Feng Q; Zhao Q; Zeng MS; Krummenacher C; Zeng YX
Theranostics; 2020; 10(13):5704-5718. PubMed ID: 32483413
[No Abstract] [Full Text] [Related]
15. A randomized lot-to-lot immunogenicity consistency study of the candidate zoster vaccine HZ/su.
Strezova A; Godeaux O; Aggarwal N; Leroux-Roels G; Lopez-Fauqued M; Van Damme P; Vanden Abeele C; Vastiau I; Heineman TC; Lal H
Vaccine; 2017 Dec; 35(48 Pt B):6700-6706. PubMed ID: 29079101
[TBL] [Abstract][Full Text] [Related]
16. High Epstein-Barr Virus Load and Genomic Diversity Are Associated with Generation of gp350-Specific Neutralizing Antibodies following Acute Infectious Mononucleosis.
Weiss ER; Alter G; Ogembo JG; Henderson JL; Tabak B; Bakiş Y; Somasundaran M; Garber M; Selin L; Luzuriaga K
J Virol; 2017 Jan; 91(1):. PubMed ID: 27733645
[TBL] [Abstract][Full Text] [Related]
17. Identification of multiple potent neutralizing and non-neutralizing antibodies against Epstein-Barr virus gp350 protein with potential for clinical application and as reagents for mapping immunodominant epitopes.
Mutsvunguma LZ; Rodriguez E; Escalante GM; Muniraju M; Williams JC; Warden C; Qin H; Wang J; Wu X; Barasa A; Mulama DH; Mwangi W; Ogembo JG
Virology; 2019 Oct; 536():1-15. PubMed ID: 31377598
[TBL] [Abstract][Full Text] [Related]
18. Safety and immunogenicity of the rVSV∆G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study.
Heppner DG; Kemp TL; Martin BK; Ramsey WJ; Nichols R; Dasen EJ; Link CJ; Das R; Xu ZJ; Sheldon EA; Nowak TA; Monath TP;
Lancet Infect Dis; 2017 Aug; 17(8):854-866. PubMed ID: 28606591
[TBL] [Abstract][Full Text] [Related]
19. Differences in the Epstein-Barr Virus gp350 IgA Antibody Response Are Associated With Increased Risk for Coinfection With a Second Strain of Epstein-Barr Virus.
Smith NA; Baresel PC; Jackson CL; Ogolla S; Toko EN; Heit S; Piriou E; Sumba OP; Middeldorp JM; Colborn KL; Rochford R
J Infect Dis; 2019 Feb; 219(6):955-963. PubMed ID: 30312417
[TBL] [Abstract][Full Text] [Related]
20. Antigenic analysis of the Epstein-Barr virus major membrane antigen (gp350/220) expressed in yeast and mammalian cells: implications for the development of a subunit vaccine.
Emini EA; Schleif WA; Armstrong ME; Silberklang M; Schultz LD; Lehman D; Maigetter RZ; Qualtiere LF; Pearson GR; Ellis RW
Virology; 1988 Oct; 166(2):387-93. PubMed ID: 2845652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
